TONABERSAT
- CAS No.
- 175013-84-0
- Chemical Name:
- TONABERSAT
- Synonyms
- SB 22045;SB 220453;TONABERSAT;SB 220453;SB220453;Tonabersat [ban, inn];Tonabersat (SB-220453);Tonabersat >=98% (HPLC);SB-220453;SB 220453;SB220453;N-((3S,4S)-6-Acetyl-3-hydroxy-2,2-diMethylchroMan-4-yl)-3-chloro-4-fluorobenzaMide;2H-Benzo(B)pyran-3-ol, 6-acetyl-4-(3-chloro-4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-
- CBNumber:
- CB3406968
- Molecular Formula:
- C20H19ClFNO4
- Molecular Weight:
- 391.82
- MDL Number:
- MFCD00944458
- MOL File:
- 175013-84-0.mol
| Boiling point | 554.5±50.0 °C(Predicted) |
|---|---|
| Density | 1.38 |
| storage temp. | 2-8°C |
| solubility | Soluble in DMSO |
| pka | 11.86±0.60(Predicted) |
| form | powder |
| color | white to beige |
| optical activity | [α]/D -100 to -110°, c = 1 in methanol |
| FDA UNII | 2XD9773ZMN |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H400 | |||||||||
| Precautionary statements | P273-P280-P305+P351+P338-P337+P313-P391 | |||||||||
| RIDADR | UN 3077 9 / PGIII | |||||||||
| NFPA 704 |
|
TONABERSAT price More Price(25)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1354 | Tonabersat ≥98% (HPLC) | 175013-84-0 | 5MG | $185 | 2023-06-20 | Buy |
| Sigma-Aldrich | SML1354 | Tonabersat ≥98% (HPLC) | 175013-84-0 | 25MG | $704 | 2023-06-20 | Buy |
| Cayman Chemical | 19796 | Tonabersat ≥95% | 175013-84-0 | 1mg | $37 | 2024-03-01 | Buy |
| Cayman Chemical | 19796 | Tonabersat ≥95% | 175013-84-0 | 5mg | $161 | 2024-03-01 | Buy |
| Cayman Chemical | 19796 | Tonabersat ≥95% | 175013-84-0 | 10mg | $283 | 2024-03-01 | Buy |
TONABERSAT Chemical Properties,Uses,Production
Uses
It is a cholinesterase inhibitor for treating and preventing migraine. An antimigraine agent.
Biological Activity
migraine is a common, recurrent and primary headache disorder. optimisation of novel cis- and trans-4-(substituted-anfido)benzopyran-3-ol derivatives has led to the identification of tonabersat (sb-220453) with potential antimigraine activity.
Biochem/physiol Actions
Tonabersat (SB-220453) exhibits anticonvulsant property. It is a member of the family of novel benzoylamino-benzopyran compounds. Tonabersat is used as a therapeutic for trigeminal nerve-induced neurovascular reflexes. In addition, it acts as a putative migraine prophylactic agent containing an unique stereospecific binding site in the brain.
in vitro
topiramate targets multiple cortical and subcortical loci, altering voltage-gated ion channels and chemical transmission to decrease abnormal brain excitability. preclinical studies have identified four properties that may account for the drug’s efficacy in epilepsy and migraine prophylaxis: (i) blockage of voltage-dependent sodium channels; (ii) augmentation of the activity of the neurotransmitter g-aminobutyric acid (gaba) at some subtypes of the gaba-a receptor; (iii) antagonism of the ampa/kainate subtype of the glutamate receptor; and (iv) inhibition of the carbonic anhydrase enzymes, particularly isozymes ii and iv [1].
in vivo
tonabersat binds selectively to a unique site in the brain. moreover, tonabersat could markedly reduce cortical spreading depression (csd) and csd-associated events and inhibite gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion. together, these findings indicate that tonabersat should have clinical application in preventing migraine attacks [2].
References
[1] silberstein sd. tonabersat, a novel gap-junction modulator for the prevention of migraine. cephalalgia. 2009;29 suppl 2:28-35.
[2] durham pl, garrett fg. neurological mechanisms of migraine: potential of the gap-junction modulator tonabersat in prevention of migraine. cephalalgia. 2009;29 suppl 2:1-6.
[3] hauge aw, asghar ms, schytz hw, christensen k, olesen j. effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. lancet neurol. 2009;8(8):718-23.
TONABERSAT Preparation Products And Raw materials
Raw materials
Preparation Products
TONABERSAT Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Alchem Pharmtech,Inc. | 8485655694 | sales@alchempharmtech.com | United States | 63711 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 19892 | 58 |
| Finetech Industry Limited | +86-27-87465837 +8618971612321 | info@finetechnology-ind.com | China | 9702 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6393 | 58 |
| Aladdin Scientific | +1-833-552-7181 | sales@aladdinsci.com | United States | 52927 | 58 |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131981 | 58 |
| J & K SCIENTIFIC LTD. | 010-82848833 400-666-7788 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 6011 | 61 |
| Beijing HuaMeiHuLiBiological Chemical | 010-56205725 | waley188@sohu.com | China | 12338 | 58 |
| Haoyuan Chemexpress Co., Ltd. | 021-58950125 | info@chemexpress.com | China | 7553 | 61 |
175013-84-0(TONABERSAT)Related Search:
1of4